Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients

Gontero, Paolo; Sylvester, Richard; Pisano, Francesca; Joniau, Steven; Eeckt, Kathy Vander; Serretta, Vincenzo; Larré, S.; Stasi, S. Di; Rhijn, Bas van; Witjes, Alfred; Grotenhuis, Anne J.; Kiemeney, Lambertus A.; Colombo, Renzo; Briganti, Alberto; Babjuk, Marek; Malmström, Per Uno; Oderda, Marco; Irani, Jacques; Malats, Núria; Baniel, Jack; Mano, Roy; Cai, Tommaso; Eugene, K.; Ardelt, Peter; Varkarakis, John; Bartoletti, Riccardo; Spahn, Martin; Johansson, Robert; Frea, Bruno; Soukup, Viktor; Xylinas, Évanguelos; Dalbagni, Guido; Karnes, R. Jeffrey; Shariat, Shahrokh F.; Palou, Joan

doi:10.1016/j.eururo.2014.06.040

Cited by 214 publications

(175 citation statements)

References 22 publications

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…It was observed to be associated with increased progression but not with increased recurrence rates in a study by Gontero et al (7). Tumor grade was the only parameter associated with higher progression rates in our series.…”

Section: Discussionmentioning

confidence: 46%

“…Prognostic factors for this patient population has recently been investigated (6,7). In the study of European Organisation for Research and Treatment of Cancer (EORTC) 30911, data of patients undergoing maintenance BCG have been evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…However, detection of immune cells in the bladder wall and cytokines in urine clarifies the action of immune system (5). However, the capacity of immune system decreases with advanced age and age has been shown to be a parameter associated with increased progression rates and decreased survival rates in patients receiving BCG (6,7,8). …”

Section: Introductionmentioning

confidence: 99%

“…In the above mentioned trials, the study populations are heterogeneous as two important factors, maintenance BCG and a second TUR, were not performed in all patients (6,7,8). Besides, in these trials, progression was defined as upstaging to T2 or higher or presence of metastatic disease (6,7,8).…”

Section: Introductionmentioning

confidence: 99%

“…Besides, in these trials, progression was defined as upstaging to T2 or higher or presence of metastatic disease (6,7,8). However, in NMIBC, progression of Ta disease to T1 disease has been shown to be important (9) and the International Bladder Cancer Group involved progression of Ta disease to T1 disease in the definition of progression (10).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effect of Age on Outcome of High-Risk Non-Muscle-Invasive Bladder Cancer Patients Treated with Second Transurethral Resection and Maintenance Bacillus Calmette-Guerin Therapy

Baltacı¹,

Bozlu²,

Yıldırım³

et al. 2016

jus

View full text Add to dashboard Cite

What's known on the subject? and What does the study add? ÖZ ABSTRACT AmaçBu çalışmada yüksek riskli kasa invaze olmayan mesane kanseri (KİOMK) nedeniyle ikinci transüretral rezeksiyon (TUR) yapılan ve idame Bacillus Calmette-Guerin (BCG) tedavisi alan hastalarda nüks ve progresyon oranlarına yaşın etkisinin değerlendirilmesi amaçlandı. gereç ve yöntemBu çok merkezli çalışmada 2005-2012 yılları arasında yüksek riskli KİOMK nedeniyle tedavi edilen hastaların verileri incelendi. İkinci TUR da kasa invaziv olmayan, indüksiyon sonrası en az 1 yıl süre ile idame BCG tedavisi alan ve en az 12 ay tedavi alan hastalar dahil edildi. Yaşın etkisi hem iki grup olarak (<70 vs ≥70 yaş) hem de on yıllık artan gruplarda incelendi. Ki-kare, Student T-test ve ANOVA testi grupların karşılaştırılması için objective To determine the effect of age on recurrence and progression rates in a population of high-risk non-muscle invasive bladder cancer (NMIBC) patients treated with a second transurethral resection (TUR) and at least 1 year of maintenance Bacillus Calmette-Guerin (BCG) therapy. Materials and MethodsIn this multicenter study, we reviewed the data of patients treated for high-risk NMIBC between 2005 and 2012. Patients without a muscleinvasive cancer on second TUR and received induction BCG and at least one year of maintenance BCG therapy and at least 12 months of follow-up after completion of maintenance BCG were included. Effect of age was analyzed both dichotomously (<70 or ≥70 years) as well as High risk non-muscle invasive bladder cancer patients should be treated with maintenance Bacillus Calmette-Guerin (BCG) to obtain a reduce the risk of progression. The exact mechanism of action of BCG has not been clearly understood. However, there is clearly an action of immune system. Capacity of immune system decreases with advanced age and age has been shown to be associated with increased progression rates and decreased survival rates in patients receiving BCG. Previous studies are heterogeneous with respect to their population and they did not evaluate the effect of age on maintenance BCG response with the definition of progression involving Ta upstaging to T1.

show abstract

Section: Discussionmentioning

confidence: 46%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of Age on Outcome of High-Risk Non-Muscle-Invasive Bladder Cancer Patients Treated with Second Transurethral Resection and Maintenance Bacillus Calmette-Guerin Therapy

Baltacı¹,

Bozlu²,

Yıldırım³

et al. 2016

jus

View full text Add to dashboard Cite

show abstract

Preliminary Exploration of the Application of Vesical Imaging‐Reporting and Data System (VI‐RADS) in Post‐treatment Patients With Bladder Cancer: A Prospective Single‐Center Study

Cao

et al. 2021

Magnetic Resonance Imaging

View full text Add to dashboard Cite

Background Vesical Imaging‐Reporting and Data System (VI‐RADS) has been shown to be effective in diagnosing muscle invasion of bladder cancer (BC) in primary patients. Purpose To evaluate the diagnostic efficacy of VI‐RADS in a BC target population which included post‐treatment patients, and to determine the repeatability. Study Type Prospective. Population Seventy‐three patients (42 with primary BC, 31 with post‐treatment BC). Field Strength/Sequence 3.0 T MRI with propeller fast spin‐echo T2WI, echo planer imaging diffusion‐weighted imaging (DWI), and dynamic contrast‐enhanced imaging (DCEI). Assessment VI‐RADS scores were independently assessed by five radiologists with different levels of experience. The diagnostic efficiency in each group (primary and post‐treatment) and of each radiologist was assessed. Statistical Tests Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), and area under the curve (AUC) in receiver operating characteristic curve analysis were calculated to evaluate VI‐RADS diagnostic performance. Interobserver agreement was assessed using weighted Kappa statistics. A P value <0.05 was considered statistically significant. Results At the corresponding cut‐off, AUC values of three groups range from 0.936 to 0.947 and AUC values of five observers range from 0.901 to 0.963. There was no significant difference between the AUCs in the primary and post‐treatment groups (P = 0.870). The cut‐off of the whole group and the post‐treatment group was ≥4, and the cut‐off of the primary group was ≥3. The Kappa values of interobserver agreements range from 0.709 to 0.923. Conclusions After expanding the target population to include post‐treatment patients, VI‐RADS still has good diagnostic efficacy and repeatability. VI‐RADS could potentially be a preoperative staging tool for post‐treatment patients. Level of Evidence 1 Technical Efficacy Stage 2

show abstract

Bladder Cancer

Faba¹,

Subiela²,

Palou³

2020

Urologic Principles and Practice

View full text Add to dashboard Cite

Prognostic Factors and Risk Groups in T1G3 Non–Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients

Cited by 214 publications

References 22 publications

Effect of Age on Outcome of High-Risk Non-Muscle-Invasive Bladder Cancer Patients Treated with Second Transurethral Resection and Maintenance Bacillus Calmette-Guerin Therapy

Effect of Age on Outcome of High-Risk Non-Muscle-Invasive Bladder Cancer Patients Treated with Second Transurethral Resection and Maintenance Bacillus Calmette-Guerin Therapy

Preliminary Exploration of the Application of Vesical Imaging‐Reporting and Data System (VI‐RADS) in Post‐treatment Patients With Bladder Cancer: A Prospective Single‐Center Study

Bladder Cancer

Contact Info

Product

Resources

About